Abstract:Lynn Webster, 1 Jeffrey Gudin 2 1 Dr. Vince Clinical Research, Overland Park, KS, USA; 2 Department of Anesthesiology and Pain Management, University of Miami, Miller School of Medicine, Miami, FL, USA Correspondence: Lynn Webster, Dr. Vince Clinical Research, 1285 3rd Avenue, Salt Lake City, UT, 84103, USA, Tel +1 801-560-1707, Email The misuse and abuse of opioid analgesics continue to pose a serious public health concern, but for some patients, opioids remain an important analgesic option. Extended-release (ER) opioid formulations are effective for treating chronic pain and are supported by multiple 12-week efficacy studies. ER opioids often contain a high opioid content, and similar to immediate-release (IR) formulations, are subject to abuse, misuse, and diversion. Unintentional misuse may also occur when ER formulations are manipulated for medicinal administration, such as crushing a dose for easier oral intake. As part of a multipronged strategy designed to fight the opioid epidemic, abuse-deterrent formulations (ADFs) were developed to deter misuse, abuse, and diversion of opioids by making manipulation more difficult and nonoral routes of administration less rewarding. Although ADF opioids have been shown to decrease rates of abuse and diversion, they are not equally effective in terms of deterring manipulation for abuse or misuse. Xtampza ER utilizes DETERx technology, which allows it to retain ER characteristics when chewed or crushed, making it the only ER opioid without a boxed warning against these types of manipulation. OxyContin was also developed as an ADF but uses RESISTEC technology, making the tablet hard to crush and viscous in aqueous solutions. ADF utilization has been hampered by patient access issues, including high prices due to lack of insurance coverage. Postmarket real-world studies demonstrate lower rates of abuse, misuse, and diversion for ADF ER opioids compared with non-ADF formulations. However, similar studies comparing abuse-related effectiveness and health care costs for ADF opioids are warranted if clinicians are expected to utilize these potentially safer opioid formulations. These studies would support further education surrounding the benefits and utilization of ADFs and manipulation potential of different ADFs. Keywords: opioid analgesics, opioid crisis, chronic pain, tamper, abuse-deterrent, extended release Pain and chronic pain (lasting >3 months) are unpleasant sensory and emotional experiences associated with or resembling those associated with potential or actual tissue damage, which are highly debilitating and affect the quality of life of many adults in the US. 1–3 In 2021, an estimated 51.6 million adults in the US were affected by chronic pain and 17.1 million adults experienced high-impact chronic pain, defined as having pain every day or on most days during a 3-month period that substantially restricted participation in life or work activities. 2 Despite opioid misuse and abuse posing a serious and challenging public health problem, for a subset of patients with refractory pain, opioid analgesics remain an important component of pain management. 4 Common prescription opioids (limited to natural, semisynthetic, and methadone) were involved in 17,000 deaths (45 deaths per day) in the US in 2021. 5 Opioid use disorder (OUD) diagnoses and fatal overdoses increased dramatically during the COVID-19 pandemic. 6 A recent analysis by the Joint Economic Committee estimated that in 2020, the economic burden of illicit and licit opioid abuse and misuse reached almost $1.5 trillion. 7 A separate analysis considering the societal costs of OUD and opioid overdose deaths found that the greatest loss was the reduced quality of life from OUD and the value of life lost due to fatal opioid overdose. 8 These findings illustrate the magnitude of OUD as a persistent public health crisis and the devastating impact it has on individuals, families, and society. Support for opioid treatment has come under scrutiny despite therapeutic benefit. Regulatory agencies including the US Food and Drug Administration (FDA) encourage the development of abuse-deterrent formulations (ADF) as part of a multipronged approach for combating opioid misuse and abuse while ensuring that appropriate patients are treated effectively. The aim of this review is to discuss the properties of the available ADF products with evidence for abuse deterrence (eg, physical and chemical barriers) and how these properties may reduce abuse potential. The barriers that limit access to effective opioid treatment are also discussed. A trial of opioid therapy may be warranted if conservative and interventional analgesic treatments fail, and an individual's risk for OUD should be taken into considerat -Abstract Truncated-

When Oxybutynin Becomes a Decoy for Oxycodone: A Case Report of Diversion Through Substitution

Opioid Analgesics-Related Pharmacokinetic Drug Interactions: from the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management

Descriptive analysis of the legal ramifications of medication diversion by pharmacy employees

Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents

Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population

Evaluation of a Drug Deactivation System for Safe Disposal of Opioids After Ambulatory Surgery

Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone

Motivations for and perspectives of medication diversion among clients of a safer opioid supply program in Toronto, Canada

Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study

Blocking Potential Metabolic Sites on NAT to Improve Its Safety Profile While Retaining the Pharmacological Profile

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users

A Mixed-Method Analysis of Reports on 100 Cases of Improper Prescribing of Controlled Substances

Influences of Software Changes on Oxycodone Prescribing at an Australian Tertiary Emergency Department: A Retrospective Review

Computerized surveillance of opioid-related adverse drug events in perioperative care: a cross-sectional study

Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Case files of the University of Massachusetts fellowship in medical toxicology: lethal dose of opioids contained in an elastomeric capsule labeled as vancomycin

Multidimensional opioid abuse deterrence using a nanoparticle-polymer hybrid formulation

Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy—Observational study

An Overview of Opioid Prescription Patterns among Non-Opioid Users Following Emergency Department Admission

Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study